Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Aug 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the best way to treat certain types of pituitary tumors called prolactinomas, specifically those classified as Knosp grades 0-2. It looks at two treatment options: medication and surgery, to see which one works better and has fewer side effects. The trial will take place in several hospitals across China, and its goal is to provide more evidence to help doctors make informed decisions about treating these tumors.

To be eligible for this trial, participants need to have a prolactin level that is more than three times the normal limit and an MRI showing a Knosp Grade 0-2 pituitary adenoma. However, people with more severe tumors (Knosp grade 3-4), those on certain medications, or those with specific health issues will not be able to participate. If you join the trial, you can expect to receive either medication or surgery as part of the study, and this will help researchers understand which treatment is more effective.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prolactin level greater than three times the normal upper limit
• • MRI indicates Knosp Grade 0-2 pituitary adenoma
• Exclusion Criteria:
• • MRI indicates Knosp grade 3-4 pituitary adenoma
• • Taking antidepressants or other psychotropic drugs
• • Patients allergic to bromocriptine or cannot tolerate surgery
• • Women defined as surgical infertility (i.e. hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or amenorrhea for more than 2 years
• • Critical illness patients, such as those with progressive consciousness disorders, cerebral hernias, and other emergency situations